Figure 3From: Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer Quality-adjusted survival (QAS) of adjuvant goserelin and adjuvant chemotherapy for premenopausal breast cancer patients.Back to article page
